Generic boniva approved for osteoporosis

March 19, 2012

(HealthDay) -- The first generic versions of the once-monthly osteoporosis drug Boniva (ibandronate) have been approved by the U.S. Food and Drug Administration.

Osteoporosis, characterized by a thinning of the bones, is the most common type of bone disease, the agency said in a news release Monday. More common in postmenopausal women, it increases the risk of fracture, especially of the hip, spine and wrist.

More than 40 million people in the United States have the disease or are at significant risk for it, the FDA said.

Approvals to produce generic Boniva have been granted to: Apotex Inc., Orchid Healthcare and Mylan Pharmaceuticals. are medically equivalent to the brand-name versions and are subject to the same quality standards, the agency said.

Generic Boniva will be accompanied by a guide that explains potential serious reactions, including esophagus problems; pain in the muscles, bones or joints; low blood-calcium levels; and uncommon thigh-bone fractures.

More common side effects include back pain, indigestion, extremity pain, diarrhea, headache and muscle pain.

Brand name Boniva, produced by Genentech, was approved by the FDA in 2003.

Explore further: FDA approves first generic versions of Zyprexa

More information: Medline Plus has more about this drug.

Related Stories

FDA approves first generic versions of Zyprexa

October 24, 2011

(AP) -- Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, an expensive treatment for schizophrenia and bipolar mood disorder.

First generic lexapro approved

March 14, 2012

(HealthDay) -- The Israeli drug maker Teva Pharmaceuticals has gained the first U.S. approval to market generic Lexapro (escitalopram) to treat depression and general anxiety disorder, the U.S. Food and Drug Administration ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.